A Study of Pyridostigmine in Postural Tachycardia Syndrome

Description

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Conditions

Postural Tachycardia Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Condition
Postural Tachycardia Syndrome
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
  • * Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.
  • * Pregnant or lactating women
  • * Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
  • * Hypothyroidism or hyperthyroidism
  • * Clinically significant coronary artery disease
  • * Medications that could interfere with autonomic testing
  • * Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month

Ages Eligible for Study

15 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Phillip A. Low, M.D., PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2025-02